[Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma]

Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):148-150. doi: 10.3760/cma.j.issn.0253-2727.2023.02.011.

[Article in Chinese]

Authors

W Y Huang¹, W Liu¹, H M Liu¹, Y Xu¹, Q Wang¹, C X Du¹, W J Xiong¹, W W Sui¹, F Tian¹, J Wang¹, S H Yi¹, G An¹, L G Qiu¹, D H Zou¹

Affiliation

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.

PMID: 36948870
PMCID: PMC10033269
DOI: 10.3760/cma.j.issn.0253-2727.2023.02.011

No abstract available

MeSH terms

Hematopoietic Stem Cell Transplantation*
Humans
Melphalan / therapeutic use
Multiple Myeloma* / therapy
Transplantation Conditioning
Transplantation, Autologous

Substances

Melphalan